Squarepoint
ONC

Squarepoint’s BeOne Medicines Ltd ONC Stock Holding History

Squarepoint’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.4M Buy
78,561
+4,437
+6% +$1.31M 0.02% 648
2026
Q1 		$22M Buy
74,124
+5,224
+8% +$1.69M 0.03% 657
2025
Q4 		$20.9M Sell
68,900
-930
-1% -$304K 0.02% 719
2025
Q3 		$23.8M Buy
69,830
+930
+1% +$282K 0.02% 657
2025
Q2 		$16.7M Sell
68,900
-570
-0.8% -$140K 0.02% 852
2025
Q1 		$18.9M Sell
69,470
-106
-0.2% -$24.8K 0.02% 716
2024
Q4 		$12.9M Sell
69,576
-3,133
-4% -$640K 0.01% 1004
2024
Q3 		$16.3M Buy
72,709
+654
+0.9% +$118K 0.03% 690
2024
Q2 		$10.3M Buy
72,055
+1,743
+2% +$269K 0.02% 931
2024
Q1 		$11M Buy
70,312
+49,320
+235% +$7.94M 0.02% 942
2023
Q4 		$3.79M Buy
20,992
+19,473
+1,282% +$3.52M 0.01% 1567
2023
Q3 		$273K Sell
1,519
-6,921
-82% -$1.37M ﹤0.01% 3234
2023
Q2 		$1.5M Buy
8,440
+4,594
+119% +$1.06M ﹤0.01% 1869
2023
Q1 		$829K Buy
+3,846
New +$923K ﹤0.01% 2009
2022
Q4 		– Sell
-2,400
Closed -$324K – 3683
2022
Q3 		$324K Sell
2,400
-1,741
-42% -$299K ﹤0.01% 2441
2022
Q2 		$670K Buy
4,141
+1,931
+87% +$302K ﹤0.01% 1847
2022
Q1 		$417K Buy
2,210
+13
+0.6% +$2.76K ﹤0.01% 2111
2021
Q4 		$595K Buy
2,197
+268
+14% +$90.5K ﹤0.01% 2027
2021
Q3 		$700K Sell
1,929
-5,342
-73% -$1.75M ﹤0.01% 1773
2021
Q2 		$2.5M Buy
+7,271
New +$2.41M 0.01% 1066
2020
Q4 		– Sell
-1,961
Closed -$562K – 3322
2020
Q3 		$562K Buy
+1,961
New +$461K 0.01% 1356
2020
Q1 		– Sell
-2,450
Closed -$406K – 2639
2019
Q4 		$406K Buy
+2,450
New +$407K ﹤0.01% 1886
2019
Q3 		– Sell
-4,179
Closed -$518K – 2729
2019
Q2 		$518K Buy
+4,179
New +$530K 0.01% 1643
2018
Q4 		– Sell
-1,657
Closed -$285K – 2289
2018
Q3 		$285K Buy
+1,657
New +$279K ﹤0.01% 1567
2017
Q4 		– Sell
-3,137
Closed -$325K – 2383
2017
Q3 		$325K Buy
+3,137
New +$234K 0.01% 1141

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Squarepoint's ONC Position: Q2 2026 in Review

Squarepoint increased its BeOne Medicines Ltd (ONC) stake by 6% in Q2 2026, buying an estimated $1.31M and bringing the position to 78,561 shares worth $22.4M. The position accounts for 0.02% of the portfolio, ranked #648.

Squarepoint first reported a position in ONC in Q3 2017 and has held it in 25 quarters since. The position peaked at $23.8M in Q3 2025. 283 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • Squarepoint held 78,561 shares of BeOne Medicines Ltd worth $22.4M as of Q2 2026.
  • Squarepoint bought 4,437 BeOne Medicines Ltd shares in Q2 2026, an estimated $1.31M.
  • BeOne Medicines Ltd made up 0.02% of Squarepoint's portfolio in Q2 2026, its #648 holding.
  • Squarepoint first reported a position in BeOne Medicines Ltd in Q3 2017 and has held it in 25 quarters since.
  • Squarepoint's BeOne Medicines Ltd position peaked at $23.8M in Q3 2025.
  • 283 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.